Company news

Allarity Therapeutics, Inc. news in 2023

Allarity Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

December 11, 2023

Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

December 4, 2023

Allarity Therapeutics to Present at Biomarkers Europe 2023

October 1, 2023

Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology

September 13, 2023

PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib

August 29, 2023

Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

July 30, 2023

Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

July 23, 2023

Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering

July 5, 2023

Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients

July 4, 2023

Allarity Therapeutics Announces Reverse Stock Split of Common Stock

June 27, 2023

Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split

June 26, 2023

Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders

June 19, 2023

First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting

May 29, 2023

Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023

April 26, 2023

Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering

April 18, 2023

Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting

April 10, 2023

Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies

March 27, 2023

Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors

March 19, 2023

Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

January 19, 2023

Decks in 2023